From September 26–28, experts gathered in the stunning Åland archipelago to discuss the latest in VWD diagnosis and management. This historic location, tied to the origins of VWD research, provided a meaningful backdrop for insightful discussions. Read the full event report on our website to learn more about the advancements shared at this significant meeting: https://bit.ly/3BpejtT #vonwillebranddisease #vwd
Octapharma
Pharmaceutical Manufacturing
Lachen, Switzerland 53,523 followers
Our passion drives us to provide new health solutions advancing human life
About us
Headquartered in Lachen, Switzerland, Octapharma is one of the largest human protein manufacturers in the world, developing and producing human proteins from human plasma and human cell lines. Octapharma employs nearly 12,000 people worldwide to support the treatment of patients in 118 countries with products across three therapeutic areas: Immunotherapy, Haematology and Critical Care. Octapharma has seven R&D sites and five state-of-the-art manufacturing facilities in Austria, France, Germany and Sweden, and operates more than 195 plasma donation centres across Europe and the US. Octapharma has 40 years of experience in patient care. Check our community guidelines: https://bit.ly/3M8ioml
- Website
-
http://www.octapharma.com
External link for Octapharma
- Industry
- Pharmaceutical Manufacturing
- Company size
- 10,001+ employees
- Headquarters
- Lachen, Switzerland
- Type
- Privately Held
- Founded
- 1983
- Specialties
- Plasma Fractionation, Haematology, Immunotherapy, and Critical Care
Locations
Employees at Octapharma
Updates
-
In 1999, we established our global headquarters in Lachen, Switzerland, starting with just 20 employees. Since then, our team has grown to 120 employees, representing over 25 nationalities and reflecting 25 years of development and success. With its picturesque lakeside setting and strategic position in Europe, Lachen, along with our dedicated global, clinical R&D, and Swiss market teams, continues to play a vital role in our vision to provide new health solutions advancing human life.
-
Octapharma Dessau’s commitment to high standards in business practices and employee experience has earned it a place as a regional finalist in the 2024 "Großer Preis des Mittelstands" (Grand Prize for Small and Medium-Sized Businesses). This recognition positively impacts Dessau-Roßlau as a business location, highlighting that this is the first time in recent years a company from the region has been a finalist for the award. Read the story here: https://bit.ly/3YBoMdi
-
-
Join our team in Lachen, Switzerland, and help develop lifesaving therapies! As a Clinical Trial Manager, you will oversee global clinical trials, manage sites and vendors, and contribute to groundbreaking research. Learn more about the opportunity and apply now: https://bit.ly/4f4tg2P
-
-
We are hiring a Group Senior Administrative Project Coordinator in Lachen, Switzerland! In this role, you will take charge of logistics, provide exceptional administrative support, and collaborate with partners to ensure seamless execution of congresses and events. Learn more about this opportunity and apply here: https://bit.ly/48fUVLP
-
-
Advancements in artificial intelligence within the healthcare sector are showing significant potential to revolutionise and expedite the diagnosis and treatment of patients with primary immunodeficiencies. Join Manish Butte, Elie Haddad, and Helen Leavis to learn about the latest scientific advances and practical applications at the Octapharma symposium at #ESID2024 on Friday, October 18, at 12:15 CET. See the details here: https://bit.ly/4eYIYfM
-
Primary immunodeficiencies are rare and present with a diverse range of symptoms, often leading to significant delays in diagnosis and treatment. These delays aggravate both mortality and morbidity. Recent advancements in artificial intelligence (#AI) within healthcare have shown great promise in revolutionising and accelerating the diagnosis and care of patients with primary immunodeficiencies. Join us at #ESID2024 on Friday, October 18 at 12:15 CET to explore the latest scientific breakthroughs and practical applications: https://bit.ly/4eYIYfM
-
-
Karin, with over 1,400 donations, and Mike, with over 1,200, are dedicated plasma donors at Octapharma. For both, what began as a simple act has evolved into a deep connection with their community and a commitment to saving lives. Their stories are a testament to the life-saving power of plasma donations and the incredible bonds formed within the Octapharma Plasma community. This week (October 7-11), we celebrate International Plasma Awareness Week and honor donors like Karin and Mike—the heart of our lifesaving mission. #IPAW2024
Meet Mike and Karin, two of Octapharma Plasma's super donors! Collectively, they have donated more than 2,600 times. Learn more about their experiences here: https://lnkd.in/exxyH3CK
-
-
World Myositis Day on September 21 brings attention to a group of rare autoimmune diseases known collectively as myositis. These diseases often lead to muscle weakness, pain, and fatigue, severely impacting mobility. Everyday tasks like climbing stairs or lifting arms above the head can become challenging. Given the complexity of these symptoms, it’s crucial to raise awareness about myositis not only among the general public but also within the medical and research communities. Increased understanding can lead to earlier diagnosis, more effective treatments, and improved quality of life for those affected by myositis. Learn more about the symptoms, diagnosis, and treatment of myositis here: https://bit.ly/3TDs2D5
-
The next patient case from our Clinical Practice online series goes live on One Source on Monday, September 23 at 17:00 CET. Join us and Natascha Marquardt for an interactive session where we will discuss bleeding management strategies using FVIII treatment in a patient with acquired haemophilia A. We look forward to answering any questions you may have. Sign up for the session here: https://bit.ly/3MLFu40 The event is for healthcare professionals only.
-